5656 related articles for article (PubMed ID: 306870)
1. A prospective study of immune responsiveness in human melanoma. I. Assessment of initial pretreatment status with stage of disease.
Pritchard DJ; Ritts RE; Taylor WF; Miller GC
Cancer; 1978 Jun; 41(6):2165-73. PubMed ID: 306870
[TBL] [Abstract][Full Text] [Related]
2. Some aspects of cell-mediated hypersensitivity in patients with melanoma.
Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E
Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
Rangel DM; Golub SH; Morton DL
Surgery; 1977 Aug; 82(2):224-32. PubMed ID: 877866
[TBL] [Abstract][Full Text] [Related]
4. Unspecific cellular immunity before therapy in patients with squamous cell carcinoma of head and neck.
Bier J; Bitter K; Nicklisch U
J Maxillofac Surg; 1978 May; 6(2):75-93. PubMed ID: 353210
[TBL] [Abstract][Full Text] [Related]
5. Biological markers and breast cancer. A multiparametric study. II. Depressed immune competence.
Mandeville R; Lamoureux G; Legault-Poisson S; Poisson R
Cancer; 1982 Oct; 50(7):1280-8. PubMed ID: 6980699
[TBL] [Abstract][Full Text] [Related]
6. Sequential evaluation of immunoreactivity in patients with melanoma undergoing surgery and adjuvant therapy.
Dionigi R; Dominioni L; Gnes F; Bonera A; Prati U; Scarponi A; Robustelli Della Cuna G; Pavesi L; Campani M
Tumori; 1980 Feb; 66(1):59-76. PubMed ID: 6966434
[TBL] [Abstract][Full Text] [Related]
7. Cell-mediated immunity in patients with carcinoma: correlation between clinical stage and immunocompetence.
Kopersztych S; Rezkallah MT; Miki SS; Naspitz CK; Mendes NF
Cancer; 1976 Sep; 38(3):1149-54. PubMed ID: 1085193
[TBL] [Abstract][Full Text] [Related]
8. Immunologic aspects of unknown primary melanoma.
Giuliano AE; Moseley HS; Irie RF; Golub SH; Morton DL
Surgery; 1980 Jan; 87(1):101-5. PubMed ID: 7350713
[TBL] [Abstract][Full Text] [Related]
9. Correlations among cutaneous reactivity to DNCB, PHA-induced lymphocyte blastogenesis and peripheral blood E rosettes.
Catalona WJ; Tarpley JL; Potvin C; Chretien PB
Clin Exp Immunol; 1975 Feb; 19(2):327-33. PubMed ID: 1082390
[TBL] [Abstract][Full Text] [Related]
10. Potentiation and arming of lymphocyte mediated immunity by sera from melanoma patients.
Vanwijck R; Bouillenne C; Malek-Mansour S
Eur J Cancer (1965); 1975 Apr; 11(4):267-76. PubMed ID: 1079770
[No Abstract] [Full Text] [Related]
11. [Evaluation of T- and B-cell immunity of regional lymph nodes in patients with skin melanoma and prognosis of the disease].
Serov AA; Kadagidze ZG
Vopr Onkol; 1983; 29(12):18-20. PubMed ID: 6607569
[TBL] [Abstract][Full Text] [Related]
12. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
13. [Skin reactions of delayed hypersensitivity in melanoblastoma].
Ryzhkov VI; Potapenkova LS; Korosteleva TA; Khachaturian LM
Vopr Onkol; 1979; 25(4):3-6. PubMed ID: 433214
[TBL] [Abstract][Full Text] [Related]
14. Malignant melanoma. Delayed hypersensitivity skin testing.
Roses DF; Campion JF; Harris MN; Gumport SL
Arch Surg; 1979 Jan; 114(1):35-8. PubMed ID: 758875
[TBL] [Abstract][Full Text] [Related]
15. In vitro assessment of immunocompetence in patients with malignant melanoma.
Golub SH; Rangel DM; Morton DL
Int J Cancer; 1977 Dec; 20(6):873-80. PubMed ID: 591127
[TBL] [Abstract][Full Text] [Related]
16. Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocyte reactivity to PHA and antigens following immunization.
de Gast GC; The TH; Schraffordt Koops H; Huiges HA; Oldhoff J; Nieweg HO
Cancer; 1975 Oct; 36(4):1289-97. PubMed ID: 1175127
[TBL] [Abstract][Full Text] [Related]
17. Cell-mediated immunity in the rheumatoid diseases. I. Skin testing and mitogenic responses in sero-negative arthritides.
Froebel K; Sturrock RD; Dick WC; MacSween RN
Clin Exp Immunol; 1975 Dec; 22(3):446-52. PubMed ID: 1083785
[TBL] [Abstract][Full Text] [Related]
18. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
19. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
Kokoschka EM; Cerni C; Micksche M
Oncology; 1977; 34(5):229-33. PubMed ID: 917456
[TBL] [Abstract][Full Text] [Related]
20. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
